Prognostic value of right ventricular dilatation on computed tomography pulmonary angiogram for predicting adverse clinical events in severe COVID-19 pneumonia.
ARDS
AVDS
COVID-19
angiogram
computed tomography
pneumonia
right ventricle dilatation
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
04
2023
accepted:
03
07
2023
medline:
16
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Right ventricle dilatation (RVD) is a common complication of non-intubated COVID-19 pneumonia caused by pro-thrombotic pneumonitis, intra-pulmonary shunting, and pulmonary vascular dysfunction. In several pulmonary diseases, RVD is routinely measured on computed tomography pulmonary angiogram (CTPA) by the right ventricle-to-left ventricle (LV) diameter ratio > 1 for predicting adverse events. The aim of the study was to evaluate the association between RVD and the occurrence of adverse events in a cohort of critically ill non-intubated COVID-19 patients. Between February 2020 and February 2022, non-intubated patients admitted to the Amiens University Hospital intensive care unit for COVID-19 pneumonia with CTPA performed within 48 h of admission were included. RVD was defined by an RV/LV diameter ratio greater than one measured on CTPA. The primary outcome was the occurrence of an adverse event (renal replacement therapy, extracorporeal membrane oxygenation, 30-day mortality after ICU admission). Among 181 patients, 62% ( Right ventricle (RV) dilatation assessed by RV/LV ratio was a common CTPA finding in non-intubated critical patients with COVID-19 pneumonia and was not associated with the occurrence of clinical adverse events.
Sections du résumé
Background
UNASSIGNED
Right ventricle dilatation (RVD) is a common complication of non-intubated COVID-19 pneumonia caused by pro-thrombotic pneumonitis, intra-pulmonary shunting, and pulmonary vascular dysfunction. In several pulmonary diseases, RVD is routinely measured on computed tomography pulmonary angiogram (CTPA) by the right ventricle-to-left ventricle (LV) diameter ratio > 1 for predicting adverse events.
Objective
UNASSIGNED
The aim of the study was to evaluate the association between RVD and the occurrence of adverse events in a cohort of critically ill non-intubated COVID-19 patients.
Methods
UNASSIGNED
Between February 2020 and February 2022, non-intubated patients admitted to the Amiens University Hospital intensive care unit for COVID-19 pneumonia with CTPA performed within 48 h of admission were included. RVD was defined by an RV/LV diameter ratio greater than one measured on CTPA. The primary outcome was the occurrence of an adverse event (renal replacement therapy, extracorporeal membrane oxygenation, 30-day mortality after ICU admission).
Results
UNASSIGNED
Among 181 patients, 62% (
Conclusion
UNASSIGNED
Right ventricle (RV) dilatation assessed by RV/LV ratio was a common CTPA finding in non-intubated critical patients with COVID-19 pneumonia and was not associated with the occurrence of clinical adverse events.
Identifiants
pubmed: 37583421
doi: 10.3389/fmed.2023.1213775
pmc: PMC10425267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1213775Informations de copyright
Copyright © 2023 Beyls, Vial, Lefebvre, Muller, Hanquiez, Besserve, Guilbart, Haye, Bernasinski, Huette, Dupont, Abou-Arab, Jounieaux and Mahjoub.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiology. 2020 Apr;295(1):202-207
pubmed: 32017661
Am J Med. 2015 Jul;128(7):747-59.e2
pubmed: 25680885
Clin Transl Imaging. 2022;10(6):663-676
pubmed: 35892066
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
Sci Rep. 2021 Sep 7;11(1):17774
pubmed: 34493763
Eur Respir J. 2012 Apr;39(4):919-26
pubmed: 21965223
Thromb Res. 2020 Dec;196:138-140
pubmed: 32866826
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Eur Radiol. 2011 Apr;21(4):730-7
pubmed: 20927526
Chest. 2020 Jan;157(1):89-98
pubmed: 31351047
Circ Cardiovasc Imaging. 2012 Jan;5(1):147-54
pubmed: 22178898
Front Med (Lausanne). 2022 Oct 04;9:824994
pubmed: 36267616
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Am J Respir Crit Care Med. 2022 Jan 1;205(1):121-125
pubmed: 34734553
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Egypt Heart J. 2022 May 8;74(1):37
pubmed: 35527310
J Clin Med. 2021 Jun 08;10(12):
pubmed: 34200990
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Crit Care. 2020 Jun 11;24(1):327
pubmed: 32527297
Front Med (Lausanne). 2022 Jul 01;9:936816
pubmed: 35847817
Anaesth Crit Care Pain Med. 2018 Dec;37(6):607-614
pubmed: 30580775
Compr Physiol. 2018 Mar 25;8(2):711-729
pubmed: 29687908
Front Med (Lausanne). 2023 Mar 22;10:1117151
pubmed: 37035332
Lancet Infect Dis. 2020 Dec;20(12):1365-1366
pubmed: 32359410
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Eur J Heart Fail. 2020 Dec;22(12):2228-2237
pubmed: 33200458
Eur Heart J Cardiovasc Imaging. 2022 Mar 22;23(4):569-577
pubmed: 34008835
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200047
pubmed: 33778560
Echocardiography. 2006 Apr;23(4):271-8
pubmed: 16640703
Crit Care. 2021 Nov 18;25(1):400
pubmed: 34794499